Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.73 |
| ▸ | CA2 | P00918 | 6/20 | 0.73 |
| ▸ | CA12 | O43570 | 5/20 | 0.73 |
| ▸ | CA7 | P43166 | 5/20 | 0.73 |
| ▸ | CA9 | Q16790 | 5/20 | 0.73 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | XDH | P47989 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL475746 | 0.87 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| Methyl 3,5-Dimethoxybenzoate SCHEMBL204865 | 0.87 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| Methyl 3,5-Dihydroxybenzoate SCHEMBL38869 | 0.85 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| SCHEMBL46504 | 0.85 | CA12 (0.91) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2663326 | 0.85 | CA1 (0.68) | CA1CA2CA12CA7CA9 | |
| SCHEMBL20944289 | 0.83 | CA1 (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL15516856 | 0.82 | CA1 (0.63) | CA1CA2CA12CA7CA9 | |
| SCHEMBL713400 | 0.82 | CA12 (0.63) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2657413 | 0.82 | CA1 (0.63) | CA1CA2CA12CA7CA9 | |
| SCHEMBL709293 | 0.82 | CA1 (0.63) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115836059-A | Process for the preparation of isoindolinone derivatives, novel intermediates used therein and process for the preparation thereof | 忠北大学校产学协力团 | 2023-03-21 | — | — | CN | claimed |
| US-20230042112-A1 | A Process For Preparing Isoindolinone Derivative, Novel Intermediates Used For The Process, And A Process For Preparing The Intermediates | Chungbuk National University Industry-Academic Coopertion Foundation (KR) | 2023-02-09 | — | — | US | claimed |
| EP-4073047-A1 | A PROCESS FOR PREPARING ISOINDOLINONE DERIVATIVE, NOVEL INTERMEDIATES USED FOR THE PROCESS, AND A PROCESS FOR PREPARING THE INTERMEDIATES | Chungbuk National University Industry-Academic Cooperation Foundation (KR) | 2022-10-19 | — | — | EP | claimed |
| WO-2021112574-A1 | A PROCESS FOR PREPARING ISOINDOLINONE DERIVATIVE, NOVEL INTERMEDIATES USED FOR THE PROCESS, AND A PROCESS FOR PREPARING THE INTERMEDIATES | CHUNGBUK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2021-06-10 | — | — | WO | claimed |
| US-12540123-B2 | Process for preparing isoindolinone derivative, novel intermediates used for the process, and a process for preparing the intermediates | CNG BIO CO., LTD. (KR) | 2026-02-03 | — | — | US | disclosed |
| EP-2603098-B1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4073047-B1 | A PROCESS FOR PREPARING ISOINDOLINONE DERIVATIVE, NOVEL INTERMEDIATES USED FOR THE PROCESS, AND A PROCESS FOR PREPARING THE INTERMEDIATES | CNG BIO CO LTD (KR) | 2025-02-26 | — | — | EP | disclosed |
| CN-119118880-A | F-18 marked PSMA inhibitor and preparation method and application thereof | 四川大学华西医院 | 2024-12-13 | — | — | CN | disclosed |
| CN-115836059-B | Method for producing isoindolinone derivative, novel intermediate used for the method, and method for producing the same | 希恩巨生物有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-114773249-B | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240262803-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | Chungdu Anticancer Bioscience Ltd (CN) | 2024-08-08 | — | — | US | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| EP-0934291-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934291-A4 | — | SMITHKLINE BEECHAM CORP (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
| EP-0351194-B1 | Thiazole derivatives having a 5-lipoxygenase-inhibiting activity | ICI PLC (GB) | 1994-06-15 | — | — | EP | disclosed |
| US-5196422-A | Antiinflammatory agents, antiallergens | ICI PHARMA (FR) | 1993-03-23 | — | — | US | disclosed |
| US-5089513-A | Antiinflammatory agents; antiallergens; asthma; side effect reduction | ICI PHARMA (FR) | 1992-02-18 | — | — | US | disclosed |
| EP-0351194-A2 | Thiazole derivatives having a 5-lipoxygenase-inhibiting activity | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-01-17 | — | — | EP | disclosed |
| US-4143055-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS | GRUPPO LEPETIT S.P.A. (IT) | 1979-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230042112-A1 | A Process For Preparing Isoindolinone Derivative, Novel Intermediates Used For The Process, And A Process For Preparing The Intermediates | DHPS, SDHA, SQLE | CA1 3596/4885CA2 4226/4885CA12 4271/4885 |
| US-20240262803-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, PNLIP, GOT2 | CA1 1979/4885CA2 2447/4885CA12 532/4885 |
| US-12540123-B2 | Process for preparing isoindolinone derivative, novel intermediates used for the process, and a process for preparing the intermediates | BDNF, APP, PSEN1 | CA1 3477/4885CA2 4655/4885CA12 4680/4885 |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, CPT1A, OAT | CA1 1835/4885CA2 2310/4885CA12 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.